Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia (Nasdaq: LQDA) will report full year 2025 financial results on March 5, 2026. A live webcast is scheduled for 8:30 a.m. Eastern Time to discuss results and provide a corporate update. A rebroadcast will be archived on the company website for one year.
Details
News Market Reaction – LQDA
On Feb 26, the day this news came out, LQDA closed 2.63% above the previous close.
Data tracked by StockTitan Argus for the Feb 26 session.
Key Figures
- Earnings date
- March 5, 2026
- Scheduled full year 2025 financial results release
- Fiscal year
- 2025
- Full year financial results to be reported
- Webcast time
- 8:30 a.m. Eastern Time
- Start time for earnings webcast and corporate update
- Archive duration
- 1 year
- Rebroadcast of webcast available on company website
Historical Context
-
Announcement of multiple clinical posters on treprostinil programs at PVRI 2026.
-
Preliminary 2025 YUTREPIA net sales and cash flow metrics highlighted commercial traction.
-
CEO presentation scheduled at the J.P. Morgan Healthcare Conference with webcast access.
-
Planned business updates at UBS and Jefferies healthcare investment conferences in Nov 2025.
-
Q3 2025 results showing YUTREPIA launch momentum and improved profitability metrics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that it will report its full year 2025 financial results on Thursday, March 5, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The webcast will be available on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
media@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.